Skip to main content
Premium Trial:

Request an Annual Quote

Nastech Licenses RNAi IP From City of Hope to Develop siRNA Drugs

NEW YORK (GenomeWeb News) — Nastech Pharmaceutical has licensed RNAi intellectual property and technology from the City of Hope, the company said today.
Nastech licensed City of Hope’s Dicer-Substrate RNA patents and technology in order to develop short-interfering RNA-based drugs for diseases related to protein over-production.
Under the terms of the deal, Nastech gained exclusive rights to “five undisclosed targets” and non-exclusive rights to siRNAs that are subject to certain City of Hope limitations.
As an example of protein over-production issues, Nastech pointed to rheumatoid arthritis and other inflammatory diseases, which are associated with the TNF-alpha protein.
The company also said it will try to use the technology to develop therapeutics that inhibit proteins “critical for viral replication.”  
Nastech CEO Steven Quay said the technology potentially offers “a better way of developing potent siRNA therapeutics” and, when joined with other Nastech properties, will allow the company to access “all fundamental IP surrounding RNAi required for us to drive our siRNA therapeutics programs forward.”
Financial terms of the deal were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.